These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10436426)

  • 1. Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor size and volume.
    Kirkali Z; Güzelsoy M; Mungan MU; Kirkali G; Yörükoglu K
    Urol Int; 1999; 62(1):21-5. PubMed ID: 10436426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor volume.
    Partin AW; Criley SR; Steiner MS; Hsieh K; Simons JW; Lumadue J; Carter HB; Marshall FF
    Urology; 1995 Feb; 45(2):211-7. PubMed ID: 7855968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum ferritin in renal cell carcinoma: effect of tumor size, volume grade, and stage.
    Singh KJ; Singh SK; Suri A; Vijjan V; Goswami AK; Khullar M
    Indian J Cancer; 2005; 42(4):197-200. PubMed ID: 16391438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between serum ferritin levels and tumour status in patients with renal cell carcinoma.
    Miyata Y; Koga S; Nishikido M; Hayashi T; Kanetake H
    BJU Int; 2001 Dec; 88(9):974-7. PubMed ID: 11851623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ferritin: a tumor marker expressed by renal cell carcinoma.
    Kirkali Z; Esen AA; Kirkali G; Güner G
    Eur Urol; 1995; 28(2):131-4. PubMed ID: 8529738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum ferritin determination: is it useful in the early diagnosis of renal carcinoma?].
    D'Addessi A; Racioppi M; Zappacosta B; Fanasca A; De Michele T; Alcini E
    Arch Ital Urol Androl; 1997 Dec; 69(5):283-6. PubMed ID: 9477611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum ferritin: a tumor marker for renal cell carcinoma.
    Essen A; Ozen H; Ayhan A; Ergen A; Tasar C; Remzi F
    J Urol; 1991 Jun; 145(6):1134-7. PubMed ID: 2033679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma.
    Miyata Y; Koga S; Nishikido M; Noguchi M; Kanda S; Hayashi T; Saito Y; Kanetake H
    Urology; 2001 Aug; 58(2):161-4. PubMed ID: 11489689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin in renal cell carcinoma: evaluation of its usefulness as a tumor marker.
    Ljungberg B; Rasmuson T; Grankvist K
    Eur Urol; 1992; 21(2):160-3. PubMed ID: 1499617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of serum ferritin in patients with renal cell carcinoma.
    Ozen H; Uygur C; Sahin A; Tekgül S; Ergen A; Remzi D
    Urology; 1995 Oct; 46(4):494-8. PubMed ID: 7571217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma thymosin-α1 level as a potential biomarker in urothelial and renal cell carcinoma.
    Jou YC; Tsai YS; Hsieh HY; Chen SY; Tsai HT; Chen KJ; Wang ST; Shiau AL; Wu CL; Tzai TS
    Urol Oncol; 2013 Nov; 31(8):1806-11. PubMed ID: 22609059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretherapeutic Plasma Fibrinogen Level is an Independent Survival Predictor in Renal Cell Carcinoma.
    Sasaki T; Onishi T
    Oncol Res Treat; 2015; 38(7-8):374-8. PubMed ID: 26278582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
    Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
    Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of tumor volume on survival in patients with renal cell carcinoma.
    Seçil M; Çullu N; Aslan G; Mungan U; Uysal F; Tuna B; Yörükoğlu K
    Diagn Interv Radiol; 2012; 18(5):480-7. PubMed ID: 22618630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
    Wechsel HW; Petri E; Bichler KH; Feil G
    Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma.
    Ramankulov A; Lein M; Kristiansen G; Meyer HA; Loening SA; Jung K
    J Cancer Res Clin Oncol; 2007 Sep; 133(9):643-52. PubMed ID: 17479289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue polypeptide-specific antigen in renal cell carcinoma.
    Höbarth K; Hallas A; Kramer G; Aulitzky W; Gomahr A; Steiner G; Marberger M
    Eur Urol; 1996; 30(1):89-95. PubMed ID: 8854074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma.
    Gayed BA; Gillen J; Christie A; Peña-Llopis S; Xie XJ; Yan J; Karam JA; Raj G; Sagalowsky AI; Lotan Y; Margulis V; Brugarolas J
    BMC Urol; 2015 Apr; 15():24. PubMed ID: 25885592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The usefulness of serum levels of CEA, CA 50, and ferritin in the management of renal cell cancer.
    Kokociñska D; Rajchel K; Nalewajka E; Zagalski K
    J Environ Pathol Toxicol Oncol; 1996; 15(2-4):279-81. PubMed ID: 9216822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum M65 as a biomarker for metastatic renal cell carcinoma.
    Yildiz I; Sen F; Kilic L; Keskin S; Duranyildiz D; Bilgin E; Disci R; Ekenel M; Darendeliler E; Bavbek S; Basaran M
    Clin Genitourin Cancer; 2013 Sep; 11(3):290-6. PubMed ID: 23391372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.